What the research found

Researchers surveyed a nationally representative sample of over 9,000 US adults across three time points between March 2024 and October 2025, tracking GLP-1/GIP receptor agonist use, reasons for use, and how people obtained these medications. The weighted prevalence of use nearly doubled, rising from about 8% to 12% over 18 months—translating to roughly 32 million Americans. This growth was driven almost entirely by weight-loss applications, which increased from 4% to 5.6% of the population, while diabetes-indicated use remained flat at around 5%.

The study revealed meaningful differences between user groups. Those taking these medications for diabetes tended to be older with more established cardiometabolic disease, while weight-loss users skewed younger, female-predominant, and relatively healthier. Crucially, about one in three users obtained their medication outside traditional pharmacy channels—through compounders, online retailers, or international suppliers. Among weight-loss users specifically, this proportion climbed to 41% using non-traditional sources, and 43% lacked conventional insurance coverage.

Why it matters for you

If you're currently using or considering a GLP-1/GIP therapy, this data highlights a widening gap between clinical evidence and real-world practice. Trial data that informs dosing, safety monitoring, and biomarker responses come from selected populations—typically older, sicker patients with diabetes. The actual user base now includes many younger, metabolically healthier individuals pursuing weight loss, which may experience different risk-benefit profiles and side-effect patterns. Your individual response and appropriate protocol should account for this distinction.

The large proportion of users sourcing medications outside traditional channels raises practical concerns. Compounded formulations, while sometimes necessary due to access barriers, lack the quality controls and pharmacokinetic consistency of FDA-approved products. If you're tracking biomarkers like fasting glucose, lipids, or inflammatory markers while using a GLP-1/GIP—or monitoring heart rate variability and sleep via wearables—the actual dose and purity you're receiving matters. Documenting exactly what formulation and source you're using becomes important context for interpreting your results and discussing them with a clinician.

The shift toward weight-loss indication also changes the safety conversation. Most long-term outcome data comes from diabetic cohorts; applying those assumptions to a leaner, younger population may not be appropriate. If you're using these agents off-label or through non-traditional access, you're essentially part of an unmonitored cohort—meaning adverse effects, tolerability shifts, or interactions may emerge that weren't captured in trials.

Caveats

• Self-reported use and indication: No biological confirmation; people may misremember or mischaracterize their medications or reasons for use.
• Non-traditional access characteristics: Compounded product composition, strength, and purity are not verified here; actual exposure is uncertain.
• Cross-sectional snapshot: Even though this is a prospective cohort, each wave is still a point-in-time assessment; causality and longitudinal outcomes are not yet established.
• Wearable data collection incomplete: Heart rate variability, sleep, and activity metrics were available but not fully detailed in this abstract—their relationship to outcomes remains to be reported.
• No safety or efficacy outcomes: This is a prevalence and characterization study; this data does not address whether non-traditional or traditional routes produce different clinical results or harm rates.